Table 1 Susceptibility testing of 38 P. aeruginosa isolates.
Antibiotics | MIC range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | S (N/%) | R (N/%) |
|---|---|---|---|---|---|
Piperacillin/tazobactam | 4/4–128/4 | 128/4 | > 128/4 | 3 (7.9%) | 24 (63.2%) |
Ceftazidime | 2–128 | 16 | 128 | 12 (31.6%) | 19 (50.0%) |
Cefpirome | 2–128 | 32 | > 128 | 8 (21.1%) | 25 (65.8%) |
Aztreonam | 4–128 | 32 | > 128 | 4 (10.5%) | 22 (57.9%) |
Imipenem | 1–32 | 32 | > 32 | 5 (13.2%) | 32 (84.2%) |
Meropenem | 0.03–32 | 8 | > 32 | 7 (18.4%) | 22 (57.9%) |
Gentamicin | 2–128 | 8 | 32 | 12 (31.6%) | 11 (28.9%) |
Amikacin | 2–32 | 8 | 16 | 37 (97.4%) | 0 |
Tobramycin | 1–128 | 2 | 4 | 37 (97.4%) | 1 (2.6%) |
Ciprofloxacin | 0.5–64 | 4 | 64 | 3 (7.9%) | 30 (78.9%) |
Polymyxin B | 0.06–2 | 0.25 | 1 | – | 0 |
